Leaflet APTIVUS 250mg soft capsules
Indicated for: HIV-1 infection
Route of administration: oral
Substance: tipranavir (protease inhibitor)
ATC: J05AE09 (Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Tipranavir is a protease inhibitor used in the treatment of HIV-1 infection in patients who have developed resistance to other antiretroviral therapies. It works by inhibiting the HIV protease enzyme, preventing the virus from replicating.
The medication is taken orally, usually in combination with ritonavir to enhance its effectiveness. The dosage and duration of treatment are adjusted based on the patient's response and treatment history.
Patients should be closely monitored to detect potential side effects, such as gastrointestinal disturbances, elevated liver enzymes, or allergic reactions. It is important for patients to strictly adhere to the treatment regimen.
Common side effects include diarrhea, nausea, fatigue, and headache. In rare cases, severe reactions such as hepatotoxicity or intracranial hemorrhages may occur. Patients should be informed of these risks before starting treatment.
General data about APTIVUS 250mg
- Substance: tipranavir
- Date of latest medicines list: 01-04-2015
- Product code: W51426001
- Concentration: 250mg
- Pharmaceutical form: soft capsules
- Quantity: 120
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.